Protective effect of Guanxinning on antipsychotic-induced cardiac impairment in long-term hospitalized psychiatric patients

Table 4 Between-group comparisons of main indicators after 12 months of intervention, mean ± SD

Measures	Guanxinning intervention group (n = 60)	Control group (n = 60)	P values
ECG parameters
QTc interphase (millisecond)	438 ± 25	465 ± 30	< 0.01
Echocardiographic indicators
LVEF (%)	58.5 ± 5.2	53.8 ± 4.8	< 0.05
LVEDD (mm)	49.8 ± 3.5	52.6 ± 3.8	< 0.05
E/A ratio, median (interquartile spacing)	1.05 (0.92-1.18)	0.93 (0.81-1.06)	0.002a
Serum biomarkers
cTnI (ng/mL), median (interquartile spacing)	0.009 (0.006-0.013)	0.014 (0.010-0.020)	< 0.001a
BNP (pg/mL), median (interquartile spacing)	52 (35-75)	78 (55-105)	< 0.001a
NT-proBNP (pg/mL), median (interquartile spacing)	95 (65-140)	145 (100-200)	< 0.001a

^aP < 0.01.

ECG: Electrocardiography; QT: The time from the start of the Q wave to the end of the T wave; QTc: Corrected QT; LVEF: Left ventricular ejection fraction; LVEDD: Left ventricular end-diastolic diameter; E/A ratio: Early maximal ventricular filling velocity/atrial maximal ventricular filling velocity; cTnI: Cardiac troponin I; BNP: B-type natriuretic peptide; NT-proBNP: High N-terminal pro-B-type natriuretic peptide.